Balogh Barbara, Pető Ágota, Fehér Pálma, Ujhelyi Zoltán, Bácskay Ildikó
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Utca 1, H-4002 Debrecen, Hungary.
Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei Körút 98, H-4032 Debrecen, Hungary.
Pharmaceutics. 2025 Jun 1;17(6):731. doi: 10.3390/pharmaceutics17060731.
Psoriasis is a chronic inflammatory skin disease characterised by increased oxidative stress, the overproliferation of keratinocytes, the accumulation of inflammatory mediators, and skin barrier damage. Although a number of therapeutic options are available, finding long-term treatments that are well-tolerated and patient-friendly treatments remains a challenge. Tapinarof is a new type of aryl hydrocarbon receptor (AhR) modulator that has recently attracted attention as a promising non-steroidal alternative. However, its application may be limited by its poor water solubility and low degree of skin penetration. Nanotechnology-based drug carriers, specially nanogels, offer new opportunities to overcome these limitations by combining the advantages of targeted drug delivery and enhanced skin penetration. Furthermore, nanogel formulations can improve skin hydration and support the restoration of skin barrier function, which are important in the treatment of psoriasis. This review focuses on current and emerging therapeutic approaches, with particular emphasis on the potential of incorporating tapinarof into nanogel formulations as a novel alternative to topical psoriasis treatment.
银屑病是一种慢性炎症性皮肤病,其特征为氧化应激增加、角质形成细胞过度增殖、炎症介质积聚以及皮肤屏障受损。尽管有多种治疗选择,但寻找耐受性良好且对患者友好的长期治疗方法仍然是一项挑战。他扎罗汀是一种新型芳烃受体(AhR)调节剂,作为一种有前景的非甾体替代药物,最近受到了关注。然而,其应用可能受到水溶性差和皮肤渗透率低的限制。基于纳米技术的药物载体,特别是纳米凝胶,通过结合靶向给药和增强皮肤渗透的优势,为克服这些限制提供了新的机会。此外,纳米凝胶制剂可以改善皮肤水合作用并支持皮肤屏障功能的恢复,这在银屑病治疗中很重要。本综述重点关注当前和新兴的治疗方法,特别强调将他扎罗汀纳入纳米凝胶制剂作为局部治疗银屑病新替代方法的潜力。
Pharmaceutics. 2025-6-1
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2024-8-6
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2016-2-26
Health Technol Assess. 2006-11
J Dermatolog Treat. 2025-12
Pharmaceutics. 2024-11-7